-
1
-
-
36849072425
-
Iron loading and its clinical implications
-
17963253 10.1002/ajh.21070 1:CAS:528:DC%2BD1cXhvFCksg%3D%3D
-
Hershko C (2007) Iron loading and its clinical implications. Am J Hematol 82:1147-1148
-
(2007)
Am J Hematol
, vol.82
, pp. 1147-1148
-
-
Hershko, C.1
-
2
-
-
36849089638
-
Concepts and goals in the management of transfusional iron overload
-
17968973 10.1002/ajh.21100 1:CAS:528:DC%2BD1cXhvFClug%3D%3D
-
Porter JB (2007) Concepts and goals in the management of transfusional iron overload. Am J Hematol 82:1136-1139
-
(2007)
Am J Hematol
, vol.82
, pp. 1136-1139
-
-
Porter, J.B.1
-
3
-
-
36248992370
-
Deferasirox for transfusion-related iron overload: A clinical review
-
18042472 10.1016/j.clinthera.2007.10.015 1:CAS:528:DC%2BD2sXhsVygtrfO
-
Lindsey WT, Olin BR (2007) Deferasirox for transfusion-related iron overload: a clinical review. Clin Ther 29:2154-2166
-
(2007)
Clin Ther
, vol.29
, pp. 2154-2166
-
-
Lindsey, W.T.1
Olin, B.R.2
-
4
-
-
34548708556
-
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review
-
17880620 10.1111/j.1537-2995.2007.01416.x 1:CAS:528:DC%2BD2sXht1elsrnN
-
Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD (2007) Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 47:1919-1929
-
(2007)
Transfusion
, vol.47
, pp. 1919-1929
-
-
Delea, T.E.1
Edelsberg, J.2
Sofrygin, O.3
Thomas, S.K.4
Baladi, J.F.5
Phatak, P.D.6
Coates, T.D.7
-
5
-
-
33749991316
-
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major
-
17018383 1:CAS:528:DC%2BD28XhtF2gsr%2FN
-
Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Alberti D (2006) Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 91:1343-1351
-
(2006)
Haematologica
, vol.91
, pp. 1343-1351
-
-
Galanello, R.1
Piga, A.2
Forni, G.L.3
Bertrand, Y.4
Foschini, M.L.5
Bordone, E.6
Leoni, G.7
Lavagetto, A.8
Zappu, A.9
Longo, F.10
Maseruka, H.11
Hewson, N.12
Sechaud, R.13
Belleli, R.14
Alberti, D.15
-
6
-
-
33846012866
-
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
-
17233848 10.1111/j.1365-2141.2006.06455.x 1:CAS:528:DC%2BD2sXislShtLY%3D
-
Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T (2007) A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136:501-508
-
(2007)
Br J Haematol
, vol.136
, pp. 501-508
-
-
Vichinsky, E.1
Onyekwere, O.2
Porter, J.3
Swerdlow, P.4
Eckman, J.5
Lane, P.6
Files, B.7
Hassell, K.8
Kelly, P.9
Wilson, F.10
Bernaudin, F.11
Forni, G.L.12
Okpala, I.13
Ressayre-Djaffer, C.14
Alberti, D.15
Holland, J.16
Marks, P.17
Fung, E.18
Fischer, R.19
Mueller, B.U.20
Coates, T.21
more..
-
7
-
-
65349152022
-
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: The ESCALATOR study
-
19187278 10.1111/j.1600-0609.2009.01228.x 1:CAS:528:DC%2BD1MXmtVyls7g%3D
-
Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A (2009) Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 82:458-465
-
(2009)
Eur J Haematol
, vol.82
, pp. 458-465
-
-
Taher, A.1
El-Beshlawy, A.2
Elalfy, M.S.3
Al Zir, K.4
Daar, S.5
Habr, D.6
Kriemler-Krahn, U.7
Hmissi, A.8
Al Jefri, A.9
-
8
-
-
33646414765
-
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia
-
16352812 10.1182/blood-2005-08-3430 1:CAS:528:DC%2BD28Xkt1Git7k%3D
-
Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107:3455-3462
-
(2006)
Blood
, vol.107
, pp. 3455-3462
-
-
Cappellini, M.D.1
Cohen, A.2
Piga, A.3
Bejaoui, M.4
Perrotta, S.5
Agaoglu, L.6
Aydinok, Y.7
Kattamis, A.8
Kilinc, Y.9
Porter, J.10
Capra, M.11
Galanello, R.12
Fattoum, S.13
Drelichman, G.14
Magnano, C.15
Verissimo, M.16
Athanassiou-Metaxa, M.17
Giardina, P.18
Kourakli-Symeonidis, A.19
Janka-Schaub, G.20
Coates, T.21
Vermylen, C.22
Olivieri, N.23
Thuret, I.24
Opitz, H.25
Ressayre-Djaffer, C.26
Marks, P.27
Alberti, D.28
more..
-
9
-
-
57049084100
-
Long-term efficacy and safety of deferasirox
-
19059055 10.1016/S0268-960X(08)70007-9 1:CAS:528:DC%2BD1MXhsFShsrw%3D
-
Cappellini MD (2008) Long-term efficacy and safety of deferasirox. Blood Rev 22[Suppl 2]:S35-S41
-
(2008)
Blood Rev
, vol.22
, Issue.SUPPL. 2
-
-
Cappellini, M.D.1
-
10
-
-
52449130092
-
Acute interstitial nephritis due to deferasirox: A case report
-
18653899 10.1093/ndt/gfn423
-
Brosnahan G, Gokden N, Swaminathan S (2008) Acute interstitial nephritis due to deferasirox: a case report. Nephrol Dial Transplant 23:3356-3358
-
(2008)
Nephrol Dial Transplant
, vol.23
, pp. 3356-3358
-
-
Brosnahan, G.1
Gokden, N.2
Swaminathan, S.3
-
11
-
-
77950492450
-
Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis
-
20470310 10.1111/j.1440-1797.2009.01183.x
-
Yew CT, Talaulikar GS, Falk MC, Clayton P, D'Rozario J, Brown M (2010) Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis. Nephrology 15:377
-
(2010)
Nephrology
, vol.15
, pp. 377
-
-
Yew, C.T.1
Talaulikar, G.S.2
Falk, M.C.3
Clayton, P.4
D'Rozario, J.5
Brown, M.6
-
12
-
-
74549200866
-
Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major
-
19934389 10.1345/aph.1M440
-
Papadopoulos N, Vasiliki A, Aloizos G, Tapinis P, Kikilas A (2010) Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother 44:219-221
-
(2010)
Ann Pharmacother
, vol.44
, pp. 219-221
-
-
Papadopoulos, N.1
Vasiliki, A.2
Aloizos, G.3
Tapinis, P.4
Kikilas, A.5
-
13
-
-
70350003769
-
Fanconi syndrome due to deferasirox
-
19493602 10.1053/j.ajkd.2009.03.013 1:CAS:528:DC%2BD1MXhsFahs7zN
-
Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M (2009) Fanconi syndrome due to deferasirox. Am J Kidney Dis 54:931-934
-
(2009)
Am J Kidney Dis
, vol.54
, pp. 931-934
-
-
Rafat, C.1
Fakhouri, F.2
Ribeil, J.A.3
Delarue, R.4
Le Quintrec, M.5
-
14
-
-
77954316682
-
Acute renal failure and Fanconi syndrome due to deferasirox
-
20466673 10.1093/ndt/gfq224 1:CAS:528:DC%2BC3cXotFehtLg%3D
-
Grange S, Bertrand DM, Guerrot D, Eas F, Godin M (2010) Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant 25:2376-2378
-
(2010)
Nephrol Dial Transplant
, vol.25
, pp. 2376-2378
-
-
Grange, S.1
Bertrand, D.M.2
Guerrot, D.3
Eas, F.4
Godin, M.5
-
15
-
-
75449084319
-
Deferasirox treatment may be associated with reversible renal Fanconi syndrome
-
20052747
-
Even-Or E, Becker-Cohen R, Miskin H (2010) Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am J Hematol 85:132-134
-
(2010)
Am J Hematol
, vol.85
, pp. 132-134
-
-
Even-Or, E.1
Becker-Cohen, R.2
Miskin, H.3
-
16
-
-
77958173787
-
Acquired proximal renal tubular dysfunction in beta-thalassemia patients treated with deferasirox
-
20733517 10.1097/MPH.0b013e3181ec0c38 1:CAS:528:DC%2BC3cXht1OisLfK
-
Yacobovich J, Stark P, Barzilai-Birenbaum S, Krause I, Pazgal I, Yaniv I, Tamary H (2010) Acquired proximal renal tubular dysfunction in beta-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol 32:564-567
-
(2010)
J Pediatr Hematol Oncol
, vol.32
, pp. 564-567
-
-
Yacobovich, J.1
Stark, P.2
Barzilai-Birenbaum, S.3
Krause, I.4
Pazgal, I.5
Yaniv, I.6
Tamary, H.7
-
17
-
-
79955671342
-
Fanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 months
-
21077910 10.1111/j.1537-2995.2010.02939.x
-
Wei HY, Yang CP, Cheng CH, Lo FS (2011) Fanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 months. Transfusion 51:949-954
-
(2011)
Transfusion
, vol.51
, pp. 949-954
-
-
Wei, H.Y.1
Yang, C.P.2
Cheng, C.H.3
Lo, F.S.4
-
19
-
-
19444365814
-
Dangerous drugs for the kidney
-
15904786 10.1016/j.arcped.2005.04.059 1:STN:280:DC%2BD2M3mt1Ojsw%3D%3D
-
Ghuysen MS (2005) Dangerous drugs for the kidney. Arch Pediatr 12:728-730
-
(2005)
Arch Pediatr
, vol.12
, pp. 728-730
-
-
Ghuysen, M.S.1
-
20
-
-
43449093775
-
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders
-
18413891 10.3324/haematol.12413
-
Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, Marchetti M, Piga A, Tura S (2008) Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 93:741-752
-
(2008)
Haematologica
, vol.93
, pp. 741-752
-
-
Angelucci, E.1
Barosi, G.2
Camaschella, C.3
Cappellini, M.D.4
Cazzola, M.5
Galanello, R.6
Marchetti, M.7
Piga, A.8
Tura, S.9
-
21
-
-
0019052791
-
Arterial blood pressure in 17,067 children and adolescents. Variation with age and height
-
6969070 1:STN:280:DyaL3M%2FmtFKmsQ%3D%3D
-
Andre JL, Deschamps JP, Gueguen R (1980) Arterial blood pressure in 17,067 children and adolescents. Variation with age and height. Arch Fr Pediatr 37:477-482
-
(1980)
Arch Fr Pediatr
, vol.37
, pp. 477-482
-
-
Andre, J.L.1
Deschamps, J.P.2
Gueguen, R.3
-
22
-
-
77955582171
-
Adaptation of an enzymatic polyfructosan assay to clinical practice
-
20541517 10.1016/j.ab.2010.06.016 1:CAS:528:DC%2BC3cXhtVaqu7jF
-
Dubourg L, Hadj-Aissa A, Ferrier B (2010) Adaptation of an enzymatic polyfructosan assay to clinical practice. Anal Biochem 405:266-268
-
(2010)
Anal Biochem
, vol.405
, pp. 266-268
-
-
Dubourg, L.1
Hadj-Aissa, A.2
Ferrier, B.3
-
23
-
-
0024720636
-
A formula to estimate the approximate surface area if height and weight be known. 1916
-
2520314
-
Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5:303-311
-
(1989)
Nutrition
, vol.5
, pp. 303-311
-
-
Du Bois, D.1
Du Bois, E.F.2
-
24
-
-
62149125881
-
New equations to estimate GFR in children with CKD
-
19158356 10.1681/ASN.2008030287
-
Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629-637
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 629-637
-
-
Schwartz, G.J.1
Munoz, A.2
Schneider, M.F.3
Mak, R.H.4
Kaskel, F.5
Warady, B.A.6
Furth, S.L.7
-
25
-
-
0033674393
-
Renal function in pediatric patients with beta-thalassemia major
-
11095025 10.1007/s004670000434 1:STN:280:DC%2BD3M7js1Ohsg%3D%3D
-
Aldudak B, Karabay Bayazit A, Noyan A, Ozel A, Anarat A, Sasmaz I, Kilinc Y, Gali E, Anarat R, Dikmen N (2000) Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol 15:109-112
-
(2000)
Pediatr Nephrol
, vol.15
, pp. 109-112
-
-
Aldudak, B.1
Karabay Bayazit, A.2
Noyan, A.3
Ozel, A.4
Anarat, A.5
Sasmaz, I.6
Kilinc, Y.7
Gali, E.8
Anarat, R.9
Dikmen, N.10
-
26
-
-
51649125405
-
Renal function in children with beta-thalassemia major and thalassemia intermedia
-
18581145 10.1007/s00467-008-0897-8
-
Smolkin V, Halevy R, Levin C, Mines M, Sakran W, Ilia K, Koren A (2008) Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr Nephrol 23:1847-1851
-
(2008)
Pediatr Nephrol
, vol.23
, pp. 1847-1851
-
-
Smolkin, V.1
Halevy, R.2
Levin, C.3
Mines, M.4
Sakran, W.5
Ilia, K.6
Koren, A.7
-
27
-
-
0031800233
-
Renal tubular function in beta-thalassemia
-
9655357 10.1007/s004670050453 1:STN:280:DyaK1czhvVSlsQ%3D%3D
-
Sumboonnanonda A, Malasit P, Tanphaichitr VS, Ong-ajyooth S, Sunthornchart S, Pattanakitsakul S, Petrarat S, Assateerawatt A, Vongjirad A (1998) Renal tubular function in beta-thalassemia. Pediatr Nephrol 12:280-283
-
(1998)
Pediatr Nephrol
, vol.12
, pp. 280-283
-
-
Sumboonnanonda, A.1
Malasit, P.2
Tanphaichitr, V.S.3
Ong-Ajyooth, S.4
Sunthornchart, S.5
Pattanakitsakul, S.6
Petrarat, S.7
Assateerawatt, A.8
Vongjirad, A.9
-
28
-
-
0037394673
-
Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia
-
12641614 10.1046/j.1365-2257.2003.00507.x 1:STN:280: DC%2BD3s7nslGiug%3D%3D
-
Koliakos G, Papachristou F, Koussi A, Perifanis V, Tsatra I, Souliou E, Athanasiou M (2003) Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clin Lab Haematol 25:105-109
-
(2003)
Clin Lab Haematol
, vol.25
, pp. 105-109
-
-
Koliakos, G.1
Papachristou, F.2
Koussi, A.3
Perifanis, V.4
Tsatra, I.5
Souliou, E.6
Athanasiou, M.7
-
29
-
-
77950530688
-
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox
-
20185899 10.1159/000287238 1:CAS:528:DC%2BC3cXktVyhsr0%3D
-
Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M (2010) Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol 123:148-152
-
(2010)
Acta Haematol
, vol.123
, pp. 148-152
-
-
Economou, M.1
Printza, N.2
Teli, A.3
Tzimouli, V.4
Tsatra, I.5
Papachristou, F.6
Athanassiou-Metaxa, M.7
-
30
-
-
79952614252
-
Renal dysfunction in patients with thalassemia
-
21332704 10.1111/j.1365-2141.2010.08477.x 1:CAS:528:DC%2BC3MXlt1Wisb0%3D
-
Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkowski JL, Neufeld EJ, Fung E, Oliveri N, Kirbys M, Giardina PJ (2011) Renal dysfunction in patients with thalassemia. Br J Haematol 153:111-117
-
(2011)
Br J Haematol
, vol.153
, pp. 111-117
-
-
Quinn, C.T.1
Johnson, V.L.2
Kim, H.Y.3
Trachtenberg, F.4
Vogiatzi, M.G.5
Kwiatkowski, J.L.6
Neufeld, E.J.7
Fung, E.8
Oliveri, N.9
Kirbys, M.10
Giardina, P.J.11
-
31
-
-
0024462523
-
Acute changes in renal function associated with deferoxamine therapy
-
2486554 1:STN:280:DyaL1MzntFKmuw%3D%3D
-
Koren G, Bentur Y, Strong D, Harvey E, Klein J, Baumal R, Spielberg SP, Freedman MH (1989) Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 143:1077-1080
-
(1989)
Am J Dis Child
, vol.143
, pp. 1077-1080
-
-
Koren, G.1
Bentur, Y.2
Strong, D.3
Harvey, E.4
Klein, J.5
Baumal, R.6
Spielberg, S.P.7
Freedman, M.H.8
-
32
-
-
18144368022
-
-
Novartis Pharmaceuticals Corporation Exjade (deferasirox)
-
Novartis Pharmaceuticals Corporation (2009) Exjade (deferasirox). Prescribing information. Available at: http://www.pharma.us.novartis.com/ product/pi/pdf/exjade
-
(2009)
Prescribing Information
-
-
-
33
-
-
0028085704
-
Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy
-
7967359 10.1038/ki.1994.295 1:STN:280:DyaK2M%2Fls1ymtw%3D%3D
-
Cianciulli P, Sollecito D, Sorrentino F, Forte L, Gilardi E, Massa A, Papa G, Carta S (1994) Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. Kidney Int 46:467-470
-
(1994)
Kidney Int
, vol.46
, pp. 467-470
-
-
Cianciulli, P.1
Sollecito, D.2
Sorrentino, F.3
Forte, L.4
Gilardi, E.5
Massa, A.6
Papa, G.7
Carta, S.8
-
34
-
-
10744230223
-
Effectiveness and safety of icl670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial
-
12747879 10.1016/S0140-6736(03)13309-0 1:CAS:528:DC%2BD3sXjs1Wltbg%3D
-
Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG (2003) Effectiveness and safety of icl670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361:1597-1602
-
(2003)
Lancet
, vol.361
, pp. 1597-1602
-
-
Nisbet-Brown, E.1
Olivieri, N.F.2
Giardina, P.J.3
Grady, R.W.4
Neufeld, E.J.5
Sechaud, R.6
Krebs-Brown, A.J.7
Anderson, J.R.8
Alberti, D.9
Sizer, K.C.10
Nathan, D.G.11
-
35
-
-
0038324389
-
Development of tridentate iron chelators: From desferrithiocin to ICL670
-
12678677 10.2174/0929867033457610 1:CAS:528:DC%2BD3sXjs1yjtbo%3D
-
Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, Alberti D (2003) Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 10:1065-1076
-
(2003)
Curr Med Chem
, vol.10
, pp. 1065-1076
-
-
Nick, H.1
Acklin, P.2
Lattmann, R.3
Buehlmayer, P.4
Hauffe, S.5
Schupp, J.6
Alberti, D.7
-
36
-
-
33745774771
-
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload
-
16818273 1:CAS:528:DC%2BD28XnslSnu7c%3D
-
Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91:873-880
-
(2006)
Haematologica
, vol.91
, pp. 873-880
-
-
Piga, A.1
Galanello, R.2
Forni, G.L.3
Cappellini, M.D.4
Origa, R.5
Zappu, A.6
Donato, G.7
Bordone, E.8
Lavagetto, A.9
Zanaboni, L.10
Sechaud, R.11
Hewson, N.12
Ford, J.M.13
Opitz, H.14
Alberti, D.15
-
37
-
-
79961008228
-
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up
-
21628399 10.1182/blood-2010-11-316646 1:CAS:528:DC%2BC3MXhtVWlsbbF
-
Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y (2011) Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 118:884-893
-
(2011)
Blood
, vol.118
, pp. 884-893
-
-
Cappellini, M.D.1
Bejaoui, M.2
Agaoglu, L.3
Canatan, D.4
Capra, M.5
Cohen, A.6
Drelichman, G.7
Economou, M.8
Fattoum, S.9
Kattamis, A.10
Kilinc, Y.11
Perrotta, S.12
Piga, A.13
Porter, J.B.14
Griffel, L.15
Dong, V.16
Clark, J.17
Aydinok, Y.18
-
38
-
-
70450133176
-
Efficacy and safety of deferasirox (Exjade®) with up to 4.5 years of treatment in patients with thalassemia major: A pooled analysis (abstract)
-
Cappellini MD, Galanello R, Piga A, Cohen A, Kattamis A, Aydinok Y, Williamson P, Rojkjaer L, Porter JB (2008) Efficacy and safety of deferasirox (Exjade®) with up to 4.5 years of treatment in patients with thalassemia major: a pooled analysis (abstract). Blood 112:5411
-
(2008)
Blood
, vol.112
, pp. 5411
-
-
Cappellini, M.D.1
Galanello, R.2
Piga, A.3
Cohen, A.4
Kattamis, A.5
Aydinok, Y.6
Williamson, P.7
Rojkjaer, L.8
Porter, J.B.9
-
39
-
-
70450127262
-
Deferasirox (Exjade®) in pediatric patients with β-thalassemia: Update of 4.7-year efficacy and safety from extension studies (abstract)
-
Piga A, Forni GL, Kattamis A, Kattamis C, Aydinok Y, Rodriguez M, Rojkjaer L, Galanello R (2008) Deferasirox (Exjade®) in pediatric patients with β-thalassemia: update of 4.7-year efficacy and safety from extension studies (abstract). Blood 112:3883
-
(2008)
Blood
, vol.112
, pp. 3883
-
-
Piga, A.1
Forni, G.L.2
Kattamis, A.3
Kattamis, C.4
Aydinok, Y.5
Rodriguez, M.6
Rojkjaer, L.7
Galanello, R.8
-
40
-
-
76849113241
-
Cystatin C levels in patients with beta-thalassemia during deferasirox treatment
-
20110177 10.1016/j.bcmd.2010.01.001 1:CAS:528:DC%2BC3cXisFKhs70%3D
-
Papassotiriou I, Margeli A, Hantzi E, Delaporta P, Sergounioti A, Goussetis E, Ladis V, Kattamis A (2010) Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. Blood Cells Mol Dis 44:152-155
-
(2010)
Blood Cells Mol Dis
, vol.44
, pp. 152-155
-
-
Papassotiriou, I.1
Margeli, A.2
Hantzi, E.3
Delaporta, P.4
Sergounioti, A.5
Goussetis, E.6
Ladis, V.7
Kattamis, A.8
-
41
-
-
53549119994
-
Desferrithiocin analogues and nephrotoxicity
-
18788724 10.1021/jm8003398 1:CAS:528:DC%2BD1cXhtFelt7%2FI
-
Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S (2008) Desferrithiocin analogues and nephrotoxicity. J Med Chem 51:5993-6004
-
(2008)
J Med Chem
, vol.51
, pp. 5993-6004
-
-
Bergeron, R.J.1
Wiegand, J.2
McManis, J.S.3
Bharti, N.4
Singh, S.5
-
42
-
-
77958161115
-
Renal Fanconi syndrome secondary to deferasirox: Where there is smoke there is fire
-
20686423 10.1097/MPH.0b013e3181ec0c4d
-
Baum M (2010) Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire. J Pediatr Hematol Oncol 32:525-526
-
(2010)
J Pediatr Hematol Oncol
, vol.32
, pp. 525-526
-
-
Baum, M.1
|